Celgene Corporation (CELG) Shares Bought by SPC Financial Inc.
SPC Financial Inc. increased its position in shares of Celgene Corporation (NASDAQ:CELG) by 32.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,825 shares of the biopharmaceutical company’s stock after buying an additional 1,675 shares during the period. SPC Financial Inc.’s holdings in Celgene Corporation were worth $849,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in CELG. Headinvest LLC acquired a new position in shares of Celgene Corporation during the fourth quarter valued at approximately $2,667,000. Edge Wealth Management LLC increased its position in shares of Celgene Corporation by 10.5% in the first quarter. Edge Wealth Management LLC now owns 15,920 shares of the biopharmaceutical company’s stock valued at $1,979,000 after buying an additional 1,518 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Celgene Corporation during the fourth quarter valued at approximately $55,336,000. Essex Financial Services Inc. increased its position in shares of Celgene Corporation by 5.8% in the fourth quarter. Essex Financial Services Inc. now owns 28,072 shares of the biopharmaceutical company’s stock valued at $3,249,000 after buying an additional 1,543 shares during the last quarter. Finally, Catawba Capital Management VA increased its position in shares of Celgene Corporation by 12.0% in the first quarter. Catawba Capital Management VA now owns 2,425 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 260 shares during the last quarter. 78.24% of the stock is currently owned by institutional investors.
Shares of Celgene Corporation (NASDAQ CELG) opened at 122.36 on Friday. The company has a market cap of $95.54 billion, a PE ratio of 45.95 and a beta of 1.82. Celgene Corporation has a 52-week low of $94.42 and a 52-week high of $127.64. The company has a 50 day moving average of $119.11 and a 200-day moving average of $119.63. Celgene Corporation also was the target of unusually large options trading activity on Friday. Investors acquired 1,785 call options on the company. This is an increase of approximately 104% compared to the average daily volume of 873 call options.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.21. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The business had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. During the same quarter last year, the firm earned $1.32 earnings per share. Celgene Corporation’s quarterly revenue was up 17.8% on a year-over-year basis. Analysts forecast that Celgene Corporation will post $7.29 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Bought by SPC Financial Inc.” was published by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/celgene-corporation-celg-shares-bought-by-spc-financial-inc-2/1371900.html.
CELG has been the topic of several recent analyst reports. Mizuho set a $130.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Sunday, February 19th. Zacks Investment Research downgraded Celgene Corporation from a “buy” rating to a “hold” rating in a report on Thursday, March 9th. BTIG Research reissued a “buy” rating and issued a $138.00 target price on shares of Celgene Corporation in a report on Wednesday, May 24th. Cann reissued an “outperform” rating and issued a $148.00 target price on shares of Celgene Corporation in a report on Friday, February 24th. Finally, Leerink Swann reissued a “market perform” rating on shares of Celgene Corporation in a report on Monday, March 20th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $139.49.
In other Celgene Corporation news, Director James J. Loughlin sold 9,250 shares of Celgene Corporation stock in a transaction on Monday, May 1st. The shares were sold at an average price of $124.00, for a total value of $1,147,000.00. Following the completion of the sale, the director now directly owns 32,169 shares of the company’s stock, valued at $3,988,956. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the sale, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Insiders have sold 28,068 shares of company stock valued at $3,459,768 in the last three months. 0.95% of the stock is owned by insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.